Strategic decisions will come into the focus of Kai Beckmann after he takes over the CEO role, in our view. We identify the Healthcare segment as being in the focus on improving its growth profile through divestments and acquisitions. Divesting the MS business would boost the segmental sales CAGR to 3.1% from 1.0%. We see more opportunity on the upside and reiterate our Outperform rating with a new target price of € 151.
Rdos. 4T'25 vs 4T'24: Ventas: 6.076 M euros (+1,9% vs +5,1% BS(e) y +3,8% consenso); EBIT: 164,0 M euros (+187,7% vs +171,9% BS(e) y +179,6% consenso); Rdos. 2025 vs 2024: Ventas: 24.811 M euros (+4,8% vs +5,6% BS(e) y +5,2% consenso); EBIT: 2.056 M euros (+53,8% vs +46,8% BS(e) y +50,3% consenso).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.